Beta Agonists and Asthma: How Do New Developments Affect Traditional Therapy?

References

• Beasley R, Pearce N, Crane J, Windom H, Burgess C. Asthma mortality and inhaled beta agonist therapy. NZ J Med 1991; 21: 753–761
   Google Scholar
• Sears M R, Taylor D R, Print C G, Lake D C, Li Q, Flannery E M, Yates D M, Lucas M K, Herbison P G. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391–1396
   PubMed Web of Science ®Google Scholar
• Spitzer W O, Suissa S, Ernst P, Horwitz R I, Harbick B, Cockcroft D, Boivin J-F., McNutt M, Buist A S, Re-Buck A S. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326: 501–506
   PubMed Web of Science ®Google Scholar
• van Metre T E. Adverse effects of inhalation of excessive amounts of nebulized isoprotenerol in status asthmatics. J Allergy 1969; 43: 101–113
   PubMedGoogle Scholar
• Benson R L, Perlman F. Clinical effects of epineph-rine by inhalation. J Allergy 1948; 19: 129–130
   PubMedGoogle Scholar
• Stolley P D. Asthma mortality: why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 1972; 105: 883–890
   PubMed Web of Science ®Google Scholar
• Crane J, Flatt A, Jackson R, Ball M, Pearce N, Burgess C, Kwong T, Beasley R. Prescribed fenot-erol and death from asthma in New Zealand, 1981–83: case-control study. Lancet 1989; 1: 917–922
   PubMed Web of Science ®Google Scholar
• Bosco L A, Knapp D E, Gerstman B, Graham C F. Asthma drug therapy trends in the United States, 1972–1985. J Allergy Clin Immunol 1987; 80(3)398–402
   PubMedGoogle Scholar
• National Center for Health Statistics. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, DHHS publication nos. (PHS) 86–1583, 85–1587, 86–1582, 86–1584, 86–1588, 87–1592, 88–1594, 89–1501, 90–1504
   Google Scholar
• Jackson R, Sears M R, Beaglehole R, Rea H H. International trends in asthma mortality: 1970–1985. Chest 1988; 94: 914–919
   PubMed Web of Science ®Google Scholar
• Löfdahl C-G., Svedmyr N. Beta-agonists—friends or foes?. Eur Respir J 1991; 4: 1161–1165
   PubMedGoogle Scholar
• Editorial. β2 agonists in asthma: relief, prevention, morbidity. Lancet 1990; 336: 1411
   PubMedGoogle Scholar
• Morley J, Sanjar S, Newth C. Viewpoint: untoward effects of beta-adrenoceptor agonists in asthma. Eur Respir J 1990; 3: 228–233
   PubMedGoogle Scholar
• Page C P. One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by β2-agonists. Lancet 1991; 337: 717–720
   PubMed Web of Science ®Google Scholar
• Nelson H, Szefler S, Martin R. Regular inhaled beta-adrenergic agonists in the treatment of bronchial asthma: beneficial or detrimental?. Am Rev Respir Dis 1991; 144: 249–250
   PubMedGoogle Scholar
• Burrows B, Lebowicz M. The β-agonist dilemma. N Engl J Med 1992; 326: 560
   PubMedGoogle Scholar
• Page C P. Are mast cells all bad?. Postgrad Med J 1991; 67: S6–S12
   Google Scholar
• Rand C S, Tashkin D, Wise R A, Nides M, Simmon M, Bleecker E R. How accurate are canister weighing and self-report as measures of metered-dose inhaler compliance in a clinical trial?. Am Rev Respir Dis 1992; 146: 1559–1564
   PubMed Web of Science ®Google Scholar
• van Schayck C P, Graafsma S J, Visch M B, Dompel-Ing E, van Weel C, van Herwaarden C LA. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol 1990; 86: 793–800
   PubMed Web of Science ®Google Scholar
• van Schayck C P, Dompeling E, van Herwaarden C LA, Folgering H, Verbeek A LM, van der Hoogen H JM, van Weel C. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomized controlled study. Br Med J 1991; 303: 1426–1431
   PubMed Web of Science ®Google Scholar
• Kraan J, Koeter G H, Mark Thwvd, Sluiter H J, de Vries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 1985; 76: 628–636
   PubMed Web of Science ®Google Scholar
• Peel E T, Gibson G J. Effects of long-term inhaled salbutamol therapy on the provocation of asthma by histamine. Am Rev Respir Dis 1980; 121: 973–978
   PubMed Web of Science ®Google Scholar
• Tashkin D P, Connolly M E, Deutsch R I, Hui K K, Littner M, Scarpace P, Abrass I. Subsensitization of beta-adrenoceptors in airways and lymphocytes of healthy and asthmatic subjects. Am Rev Respir Dis 1982; 125: 185–193
   PubMed Web of Science ®Google Scholar
• Harvey J E, Tattersfield A E. Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. Thorax 1982; 37: 280–287
   PubMed Web of Science ®Google Scholar
• Vathenen A S, Knox A J, Higgins B G, Britton J R, Tattersfield A E. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988; 1: 554
   PubMed Web of Science ®Google Scholar
• Bel E H, Zwinderman A H, Timmers M C, Dijkman J H, Sterk P J. The protective effect of a beta2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease. Thorax 1991; 46: 9–14
   PubMed Web of Science ®Google Scholar
• Shepherd G L, Hetzel M R, Clark T JH. Regular versus symptomatic aerosol bronchodilator treatment of asthma. Br J Dis Chest 1981; 75: 215
   PubMedGoogle Scholar
• Patakas D, Maniki E, Tsara V, Daskalopoulou. Intermittent and continuous salbutamol rotacaps inhalation in asthmatic patients. Respiration 1988; 54: 174–178
   PubMedGoogle Scholar
• Beswick K BJ, Pover G M, Sampson S. Long-term regularly inhaled salbutamol. Cur Med Res Opinion 1986; 10(4)228–234
   PubMed Web of Science ®Google Scholar
• Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, Sovijä A, Stenius-Aarniala B, Svahn T, Tammivaara R, Laitinen L A. Comparison of a β2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl Med J 1991; 325: 388–392
   PubMed Web of Science ®Google Scholar
• Laitinen L A, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a β2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90: 32–34
   PubMed Web of Science ®Google Scholar
• Page C P. Beta agonists and the asthma paradox. J Asthma 1993; 30(3)
   PubMedGoogle Scholar
• Sheffer A L. International consensus report on the diagnosis and management of asthma. Clin Exp Allergy 1992; 22(1)
   Google Scholar
• Sheffer A L. Guidelines for the diagnosis and management of asthma. J Allergy Clin Immunol 1991; 88(3)
   Google Scholar
• Repsher L H, Anderson J A, Bush R K, Falliers C J, Kass I, Kemp J P, Reed C, Siegel S, Webb D R. Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. Chest 1984; 85(1)34
   PubMedGoogle Scholar
• Flatt A, Cuyers C, Windom H, Beasley R, Pardie G, Crane J. The cardiovascular effects of inhaled fenot-erol alone and during treatment with oral theophyl-line. Chest 1989; 96: 1317–1320
   PubMedGoogle Scholar
• Jenne J W. The role of selectivity in determining response to beta2 agonists. J Asthma 1991; 28(5)341–347
   PubMed Web of Science ®Google Scholar
• Wong C S, Pavord I D, Williams J, Britton J R, Tattersfield A E. Bronchodilator, cardiovascular, and hypokalemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990; 336: 1396–1399
   PubMed Web of Science ®Google Scholar
• Löfdahl C G, Chung K F. Long acting β2 adrenoceptor agonists: a new perspective in the treatment of asthma. Eur Respir J 1991; 4: 218–226
   PubMedGoogle Scholar